ClinicalTrials.gg

Program

Iron

Also written as “PA21”, “PA21 (2.5 g tablet containing 500 mg iron)” and “CTX001 With Iron”.

Its studies are mostly in Hyperphosphatemia · Anemia · Renal Insufficiency, Chronic · Colorectal Neoplasms, led by 4 companies.

Furthest: phase 4, since Mar 24, 201117 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL100 open or runningphase 3since Mar 24, 2011Jan 9, 2009none ahead
Kissei Pharmaceutical50 open or runningphase 3since Apr 12, 2013Jan 26, 2012none ahead
Cajal Therapeutics11 open or runningearly phase 1since May 5, 2026May 5, 2026none ahead
J. Uriach10 open or runningphase 4since Sep 16, 2005Sep 16, 2005none ahead

Also a collaborator on its studies: Fresenius Medical Care.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2005First study: phase 4 study in Colorectal NeoplasmsNew to J. UriachJ. Uriach · NCT00199277 · 150 enrolled · Spain
  2. Jan 9, 2009CSL's first study: phase 2 study in Renal Insufficiency, ChronicNew to CSLCSL · NCT00824460 · 154 enrolled · United States, Bulgaria, Croatia and more
  3. Mar 24, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisCSL · NCT01324128 · 1,059 enrolled · United States, Austria, Belgium and more
  4. Mar 25, 2011Phase 1 study in Drug Interaction PotentiationCSL · NCT01324752 · 36 enrolled · United States
  5. Sep 12, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisCSL · NCT01464190 · 659 enrolled · United States, Austria, Belgium and more
  6. Sep 16, 20112 phase 1 studies in HealthyCSL · NCT01438359, NCT01452906
  7. Nov 16, 20112 phase 1 studies in Drug Interaction PotentiationCSL · NCT01477424, NCT01477411
  8. Jan 26, 2012Kissei Pharmaceutical's first study: phase 2 study in HyperphosphatemiaNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01521494 · 183 enrolled · Japan
  9. Apr 12, 2013Phase 3 study in HyperphosphatemiaKissei Pharmaceutical · NCT01833494 · 161 enrolled · Japan
  10. May 7, 20133 phase 3 studies in HyperphosphatemiaKissei Pharmaceutical · NCT01852682, NCT01850641, NCT01850602
  11. Jul 5, 2017No phase study in AnemiaCSL · NCT03214627 · 88 enrolled · United Kingdom
  12. Aug 21, 2018Phase 3 study in HyperphosphatemiaCSL · NCT03644264 · 286 enrolled · China
  13. May 5, 2026Cajal Therapeutics's first study: early phase 1 study in AnemiaNew to Cajal TherapeuticsCajal Therapeutics · NCT07577817 · 72 planned · Australia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07577817Anemia · AustraliaEarly 1RecruitingCajal TherapeuticsOct 202672
NCT03644264Hyperphosphatemia · China3CompletedCSLAug 21, 2020286
NCT03214627Anemia · United Kingdom–TerminatedCSLMay 21, 201988
NCT01852682Hyperphosphatemia · Japan3CompletedKissei PharmaceuticalMar 2014
NCT01850641Hyperphosphatemia · Japan3CompletedKissei PharmaceuticalDec 201335
NCT01850602Hyperphosphatemia · Japan3CompletedKissei PharmaceuticalDec 2013213
NCT01833494Hyperphosphatemia · Japan3CompletedKissei PharmaceuticalAug 2014161
NCT01521494Hyperphosphatemia · Japan2CompletedKissei PharmaceuticalJul 3, 2012183
NCT01477424Drug Interaction Potentiation · United States1CompletedCSLFeb 201245
NCT01477411Drug Interaction Potentiation · United States1CompletedCSLJan 201242
NCT01452906Healthy · United States1CompletedCSLDec 201145
NCT01438359Healthy · United States1CompletedCSLSep 201142
NCT01464190Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more3CompletedCSLOct 2012659
NCT01324752Drug Interaction Potentiation · United States1CompletedCSLJun 201136
NCT01324128Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more3CompletedCSLApr 20121,059
NCT00824460Renal Insufficiency, Chronic · United States, Bulgaria, Croatia and more2CompletedCSLOct 2009154
NCT00199277Colorectal Neoplasms · Spain4UNKNOWNJ. Uriach150

How it is read

Names in the registry

  • “PA21”, 11 entries
  • “PA21 (2.5 g tablet containing 500 mg iron)”, 2 entries
  • “CTX001 With Iron”, 1 entry
  • “IV iron”, 1 entry
  • “1.25 g PA21 (250 mg iron)”, 1 entry

Codes read as this program: PA21.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.